Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting
09 Noviembre 2021 - 7:05AM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), today announced the presentation of preclinical data
highlighting the potential of neoantigen-specific TCR-T cells for
the treatment of solid tumors at the Society for Immunotherapy of
Cancer 2021 Annual Meeting.
“We are pleased to share preclinical data
demonstrating the versatility of our Sleeping Beauty technology to
develop neoantigen-specific TCR-T cells with the potential to
address a wide range of solid tumor indications,” commented
Raffaele Baffa, M.D., Ph.D., Chief Medical Officer & EVP,
Research & Development. “Our TCR-T library approach allows us
to develop safe, effective and durable therapies for any patient
with a matching neoantigen/HLA combination within our library. We
are working diligently to initiate our Phase 1/2 TCR-T Library
trial in the first half of 2022 as well as continue to expand our
library of TCRs in order to increase the pool of eligible patients
who could benefit from these therapies.”
Details of Ziopharm’s SITC 2021 presentation are as follows:
Title: Neoantigen-specific
TCR-T cells targeting shared hotspot mutations for adoptive cell
therapy in common epithelial cancersPresenter:
Drew Deniger, Ph.D., Ziopharm OncologyDate/Time:
Saturday, Nov. 13, 2021 from 7:00 a.m. – 8:30 p.m.
ETLocation: Walter E. Washington Convention
Center, Hall EAbstract Number: 226
In the study presented at SITC, Ziopharm’s
non-viral gene transfer technology, Sleeping Beauty, was used to
develop TCR-T cells targeting EGFR, KRAS and p53 neoantigens, which
are present in cancer cells but not in normal tissue, and are
presented by a variety of human leukocyte antigen (HLA) molecules
on the cancer cell surface. Ziopharm’s Sleeping Beauty technology
exhibited greater than 60% expression of the introduced
neoantigen-specific TCRs in the generated TCR-T cells. The study
demonstrated that the neoantigen-specific TCR-T cells successfully
targeted tumor cells expressing EGFR, KRAS and p53 neoantigens in
conjunction with the matching HLA restriction. Importantly, these
TCR’s did not recognize cells lacking the matching mutations and
HLA restrictions.
About Ziopharm Oncology,
Inc.Ziopharm is a clinical-stage cell therapy company,
focused on developing T-cell receptor (TCR) therapies for a wide
range of solid tumor indications. The Company’s non-viral Sleeping
Beauty gene transfer platform has enabled the development of a
unique TCR-T Library. This library of neoantigen-specific TCR-T
cells is able to effectively target tumor cells expressing
neoantigens including KRAS and TP53, while minimizing off-target
effects and toxicity. The Company has clinical and strategic
collaborations with The University of Texas MD Anderson Cancer
Center and the National Cancer Institute. For more information,
please visit www.ziopharm.com.
Forward-Looking Statements
Disclaimer This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as “may,” “will,” “could,” “expects,” “plans,”
“anticipates,” and “believes.” These statements include, but
are not limited to, statements regarding the Company's business and
strategic plans, the timing of activities relating to the Company’s
GMP facility, the execution of potential future partnerships or
transactions, and the timing of the Company's research and
development programs, including the anticipated dates for enrolling
patients in the Company’s TCR-T clinical trial. Although Ziopharm’s
management team believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Ziopharm, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include,
among other things, changes in the Company’s operating plans that
may impact its cash expenditures, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Ziopharm’s product candidates will advance
further in the preclinical research or clinical trial process,
including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive
final approval from the U.S. FDA or equivalent foreign regulatory
agencies and for which indication; the strength and enforceability
of Ziopharm’s intellectual property rights; competition from other
pharmaceutical and biotechnology companies as well as risk factors
discussed or identified in the public filings with the Securities
and Exchange Commission made by Ziopharm, including those risks and
uncertainties listed in the most recent Form 10-Q and Form 10-K
filed by Ziopharm with the Securities and Exchange Commission. We
are providing this information as of the date of this press
release, and Ziopharm does not undertake any obligation to update
or revise the information contained in this press release whether
as a result of new information, future events, or any other
reason.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024